How Semaglutide Lasts a Full Week in Your Body

Why your body would normally clear a GLP-1 signal in minutes

The body produces its own GLP-1 naturally, mainly in the gut lining after a meal. It tells the pancreas to release insulin, slows how fast food leaves the stomach, and signals to the brain that you have eaten enough. Useful signals, but fleeting ones. An enzyme called DPP-4 breaks native GLP-1 down within two to three minutes of release, and the kidneys filter out whatever is left. That rapid clearance is fine for a meal-time pulse, but it makes natural GLP-1 useless as a medicine you could inject once and feel for days.

Early GLP-1 medicines solved this by requiring daily injections. Semaglutide solved it differently. Novo Nordisk's chemists attached a long C18 fatty-acid chain to the semaglutide molecule via a linker, which causes it to bind reversibly to albumin once injected under the skin. Albumin is large, circulates for weeks, and is not filtered by the kidneys, so anything hitching a ride on it escapes the rapid clearance that catches free GLP-1. The result is a molecule with a plasma half-life of around seven days, matching the weekly injection schedule almost perfectly. You can read more about the mechanism in the full pharmacology of semaglutide.

Understanding this matters for a practical reason: it tells you why the effect does not stop abruptly on day seven. Plasma levels decline gradually, so appetite and gastric-emptying effects taper rather than cut off.

What happens inside your body across those seven days

After a subcutaneous injection into the abdomen, thigh or upper arm, semaglutide is absorbed slowly through the lymphatic system before entering general circulation. Peak plasma concentration typically arrives somewhere between one and three days post-injection, according to the NHS patient information on semaglutide. From that peak, levels decline over the remaining days, but they do not fall to zero before the next dose is due, they reach a steady-state plateau after roughly five weeks of weekly injections, which is also when many patients begin to notice the most consistent reduction in appetite.

At the receptor level, semaglutide binds GLP-1 receptors in the brain (particularly the hypothalamus and brainstem areas involved in hunger regulation), in the stomach wall (slowing gastric emptying), and in the pancreas (supporting insulin release in a glucose-dependent way). None of these effects require the molecule to be at peak concentration; they persist across the concentration curve. That is partly why the first week of treatment can feel different from later weeks, the body has not yet built up that steady-state plateau.

For people curious about how the weekly rhythm changes over months, the week-by-week Wegovy timeline covers what clinical trial participants reported at each stage.

How the seven-day pharmacology shapes the decisions you and a prescriber make

The long half-life has real-world implications that are worth thinking through before you start treatment. The most practical: if you miss a dose, the slow elimination means meaningful semaglutide activity continues for several days, which is why clinical guidance allows a missed dose to be taken up to five days late, after that, skip it and wait for your next scheduled day. The patient FAQs cover missed-dose questions in more detail, though the definitive answer always comes from the Patient Information Leaflet and your own prescriber.

The long half-life also matters when stopping. Side effects, appetite changes and any impact on your oral contraceptive pill absorption do not disappear overnight, they wind down gradually over the following weeks. Women on oral contraceptives should discuss this timing with their prescriber, since NHS guidance highlights that semaglutide does not appear to carry the same pill-absorption concern as tirzepatide, but the broader contraception discussion remains part of any responsible clinical review. You can find context on how Wegovy is used in practice and, for anyone considering the cost side of ongoing treatment, the Wegovy cost guide sets out what private prescriptions typically involve.

For people who exercise regularly, the pharmacology intersects with how muscle responds to a calorie deficit over the weekly cycle, something the guide on semaglutide and weight training explores. And because semaglutide is a prescription-only medicine, none of these decisions about timing, exercise or stopping are ones to make independently; a prescriber who knows your full history is the right person to advise you. If you would like that clinical review, our prescribers are available seven days a week, speak to our prescribers through a free consultation and a GPhC-registered clinician will assess your situation the same day.

The NICE technology appraisal for semaglutide (TA875) sets out the clinical evidence base the NHS uses when recommending it, and is a useful read for anyone wanting the formal efficacy and safety summary.